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INTRODUCTION
The mere idea of altering the human germ line has caused
excitement as well as fears since decades. The good and,
in particular, the dubious motives for such interventions
and the anticipated troublesome outcomes have been a
recurring theme in literature, art, movies. Until recently,
these were merely science ﬁction scenarios. Yet, consid-
erations about the impact of potential future alteration of
the human germ line played a prominent role already in
debates ahead of the ﬁrst clinical trials with somatic gene
therapy in 1985 (Anderson, 1985; Fletcher, 1985). Now,
three decades later, human germ line modiﬁcation has
become a scientiﬁc reality with the experiment on CRISPR/
Cas9-mediated gene editing in human-tripronuclear-zy-
gotes by Liang et al., as published in this journal (Liang
et al., 2015).
CURRENT RESEARCH
While studies in animal models, including mammals, have
shown that on-target germ line editing is possible, Liang
et al. report a long list of obstacles and in particular off-target
effects that they encountered in edited human germ line
cells. The authors emphasize that any clinical application of
CRISPR/Cas9 for human germ line alteration will still need
much research before it can go ahead. That is true in any
case, but the speed of developments in genome editing is
unprecedented and greatly improved methods are available
for research already now (Davis et al., 2015; Maruyama
et al., 2015; Yang et al., 2014).
Also, Liang et al. used tripronuclear zygotes that are
being discarded in IVF-procedures because they lack
developmental potential—unless, ‘rescued’ by the removal
of one sperm nucleus (Kattera and Chen, 2003). Other
researchers have optimized that procedure, suggesting that
such repaired zygotes could soon become a more common
option in assisted reproduction (Fan et al., 2014). This may
raise theoretical questions about developmental potential
after enucleation ‘therapy’, and the research use of such
abnormal zygotes, that in natural reproduction, however, will
perish.
For Liang et al. the use of abnormal fertilized zygotes
underscores the absence of any intention to explore further
embryonal development in vitro or in vivo, thereby at least
formally avoiding some of the ethics controversies. However,
their particular protocol should not distract from the possi-
bility of conducting same experiments on intact diploid
zygotes, which in many places is subject to restrictions or is
prohibited. In the US there is a difference between federal
and privately funded research (Reardon, 2015). Moreover,
state regulations differ. The NIH has issued a ban on funding
of any human germ line editing research (Statement on NIH
funding of research using gene-editing technologies in
human embryos, 2015). In Europe regulations differ greatly
between countries (EuroStemCell, 2015). Germany, one of
the larger European countries with major research resour-
ces, is known for its very restrictive Embryo Protection Act
(The Embryo Protection Act, 1990). Prohibited is the “im-
proper use of human embryos”, that is use for any purpose
other than bringing about a pregnancy. Also, the alteration of
human germ line cells is prohibited if intended to be used in
human procreation. This would preclude in Germany e.g.
any genome editing in sperm cells.
DEVELOPMENTS AND FUTURE APPLICATIONS
Altogether, it is realistic to consider successful CRISPR/
Cas9-mediated gene editing in diploid zygotes followed by
normal embryonal and fetal development until term birth will
be available in the foreseeable future, as one additional
option in assisted reproduction.
A recent development is an application to the UK Human
Fertilisation and Embryology Authority (HFEA) for a licence
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to use germ line genome editing for research into recurrent
miscarriage (Cressey et al., 2015).
Current clinical options, for with acceptance differs widely
among individuals and societies, range from the use of donor
gametes—in vivo or in vitro—to preimplantation genetic
diagnosis with embryo selection and, recently mitochondrial
DNA transfer. All these interventions stirred emotional
debates when ﬁrst introduced, but found a place in clinical
practice or are expected to do so, as in the case of mito-
chondrial DNA transfer. Through careful selection for or
against traits, all of those methods aim at improving the
heritable traits of the future child, in particular by eliminating
genetic disease traits. The results of such intentional trait
selection at the level of the individual—and possible progeny
—are no more than a minor factor in the naturally occurring
dynamic changes to human germ lines at the level of human
populations that are caused by many different factors. None
of these has been disruptive of ‘humankind’ or ‘humanity’.
EMERGING TECHNOLOGIES—THE COME-BACK
OF A DEBATE
While the technology is new, the arguments concerning
ethical aspects and potential impact on society mirror those
of the debates in the eighties and the nineties—with the
Human Genome Project in its earliest stages—when somatic
gene therapies raised concerns about not-intended germ
line alteration as a side effect (Human Genome, 1989;
Lunshof and Zimmerli, 1992). Uncertainty about possible
harmful outcomes can be assumed to be much greater when
the genome alteration is accidental—and harm may go
unnoticed for long—than when interventions are targeted
and have been tested in model systems, and mathematical
predictions can be made. While uncertainty about outcomes
can complicate ethical analysis, it is not a moral criterion
itself, as sometimes suggested in the recent debate (Lan-
phier and Urnov, 2015). Harmful consequences can make an
act morally objectional, as much as beneﬁcial outcomes can
make a course of action recommendable. Uncertainty as
such is not a sufﬁcient basis for judgement, it needs further
speciﬁcation.
The still open biological questions concerning human
germ line editing can only be resolved through extensive
basic research. Clinical trials cannot begin until those
questions have been answered, and the burden of respon-
sibility is here on the researchers who are involved in the
ﬁeld. Addressing the ‘societal’ questions can be less easily
assigned to speciﬁc groups or individuals, as it is not clear
who has what role and what responsibilities, moreover, what
do we mean when referring to ‘society’? The usual reference
to broad societal discussion is well intended and sounds
correct, but actually merely adds to vagueness on where
decisions are made and by whom.
The ‘uptake’ question is much clearer. Once germ line
genome editing becomes available as an option in assisted
reproduction, there will be people who want to use it while
many others may never opt for this technology.
FEASIBILITY, USE, AND AVAILABILITY—HUMAN
GERM LINE EDITING IN PRACTICE
The roles and responsibilities in human germ line editing can
also be outlined by, ﬁrst, looking at the beginnings, namely at
the developers, the scientists who enable the technology
and their responsibility for feasibility and safety. Second, by
looking at the other end of the development phase, namely
the uptake of the technology and the responsibility of the
individuals who wish to make use of it.
The actual availability of the technology, however, can-
not be described in any clear-cut way, as it will be deter-
mined by the laws and regulations of a given country, the
international and national guidelines of the professional
associations, and the prevailing social and cultural norms in
a population.
Feasibility and biological safety
Technical feasibility and biological safety are preconditions
for any next steps towards development and implementation
of the technology. It is the role of the scientists to conduct
highest quality fundamental research. In genome engineer-
ing, the biologists and molecular engineers are those who
are responsible in the ﬁrst place. The work in the lab is
subject to biosafety regulations and rules for good laboratory
practice (GLP). In addition, national or institutional regula-
tions may apply when work is done using human bodily
material. These rules vary among countries, and determine
‘availability’ (see also below). Feasibility and safety are glo-
bal. While hurdles may be encountered at an early stage,
one should keep in mind that these likely will be transient.
Box 1. Alteration of the human germ line
New germ lines are being created continuously, as with every act
of procreation every new child has a novel, unique germ line—the
only exception being identical twins. Human germ lines are being
altered as they are damaged through environmental and
occupational exposures and through our own personal life style
choices (Yauk et al., 2015; Fowler et al., 2014). Besides, there is
the foreseeable but unavoidable damage—unless rescue
protocols can be used—to the germ line as a side effect of
medical treatments, in particular though radiation and
chemotherapy where an individual trade-off has to be made
between harms and beneﬁts. Somatic gene therapy can affect
the germ line as an unintended side effect.
At the level of populations, environmental pressure can, through
positive selection, lead to germ line enhancement in individuals
with traits that are not found ‘naturally’ in individuals in other
populations, adaptation to living at high-altitude is one well-
known example (Valverde et al., 2015). The persistence, in
populations exposed to malaria, of sickle-cell polymorphism with
heterozygote advantage is another example of adaptation to
environmental pressure, while the trait over time disappears
when malaria is eradicated (Hedrick, 2012).
COMMENTARY Jeantine E. Lunshof










Therefore, arguments assuming the technology is ultimately
“impossible” or “unsafe” may not be sustainable over time.
As in other areas, the criteria for good laboratory practice in
the work with human reproductive cells and embryos are
subject to consensus in the discipline and it is the role of the
professional societies to set the standards that guide the
research in the ﬁeld (The ISSCR Statement on Human
Germline Modiﬁcation, 2015). Good practices and safety,
however, should not be confused with acceptability of risks—
those judgements are ultimately personal, and perceptions
differ also among researchers.
Use
In the end, individuals decide about the use of the technology.
Individuals or couples, in their role of prospective parents,
decide to use—or not to use—reproductive technologies. As
before, their options range from abstaining from having their
biologically own children to use of the most advanced
assisted procedures, and their prospective parenthood
comes with a speciﬁc responsibility. This will not be different
when germ line genome editing will be among the options.
Moreover, the technology must be reliable and safe, meeting
the highest standards at the given point in time. Individual
choice may be limited by actual availability in the same way
as is currently the case with among other options preim-
plantation genetic diagnosis, gamete donation or surrogacy.
As long as there are national or regional differences, people
will travel to those places where for them relevant proce-
dures are being offered.
On the other hand, no one should be put under pressure—be
it by their family or by their government—to make a particular
reproductive choice.
Availability
While feasibility and safety are universal conditions, and the
use of assisted reproduction is based on personal decisions,
the actual availability of options is not in the hands of either
scientists or propspective parents. The real-world availability
of assisted reproductive technologies depends on rules that
permit or restrict research activities as well as personal use
—and those rules and regulations vary nationally, regionally,
locally. In addition, strong moral value-based arguments
dominate the debate, which makes universal agreement
hard to attain even within countries or among population
groups. Yet, in most if not all commentaries, ‘society’ is
referred to as the key place of decision-making, often with
the ideal of global consensus. That latter goal is vague and
unrealistic, and historical attempts at creating rules that
should be binding worldwide—as among United Nations
member states—have ultimately failed, as recently detailed
in an overview by Isasi and Knoppers (Isasi and Knoppers,
2015). On 2 October 2015, UNESCO released the Report of
the IBC on Updating Its Reﬂection on the Human Genome
and Human Rights addressing recent developments in bio-
medicine with focus on genetics and genomics, including
genome editing (International Bioethics Committee (IBC),
2015). While conservative in tone and calling for restrictions,
such a document has no legally binding force.
PUTTING CONSEQUENCES IN PERSPECTIVE
The potential disruptive effect of human germ line editing
seems very small, compared to the potential effects of other
applications of high precision genome editing, for example,
the use of gene editing that inﬂuences ecosystems (Lunshof,
2015). At this moment, the use of CRISPR-based alterations
in wild animal populations, in combination with a gene drive,
is considered the most impactful application of genome
editing. In this scenario, the genome alterations rapidly
spread through a wild animal or plant population and the
engineered organisms are self-propagating, thereby enabling
the reduction or elimination of disease vectors, pests, and
invasive species. Unintentional or premature release of
engineered organisms from the laboratory can have far-
reaching consequences that may affect the environment and
human health and well-being (Akbari et al., 2015).
Therefore, the case of genome editing for ecosystem
management requires decision-making at an appropriate
scale and global deliberations are needed that take into
account a diversity of value systems as well as effective
modes of governance (Oye et al., 2015).
The case of using CRISPR/Cas9 for human germ line
interventions is fundamentally different, as inﬂuencing heri-
table traits in humans will have few consequences beyond
the individual, the line of descendants, and their communi-
ties. The concrete decision to make use of the technique will
ultimately be a personal one, as with any decision con-
cerning reproduction, whether assisted or not.
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